{
    "Trade/Device Name(s)": [
        "BD MAX\u2122M MRSA Assay"
    ],
    "Submitter Information": "GeneOhm Sciences Canada Inc. (BD Diagnostics)",
    "510(k) Number": "K120138",
    "Predicate Device Reference 510(k) Number(s)": [
        "K093346"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NQX",
        "OOI"
    ],
    "Summary Letter Date": "June 15, 2012",
    "Summary Letter Received Date": "June 18, 2012",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.1640"
    ],
    "Regulation Name(s)": [
        "Antimicrobial susceptibility test powder"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Methicillin-resistant Staphylococcus aureus (MRSA) DNA"
    ],
    "Specimen Type(s)": [
        "Nasal swab"
    ],
    "Specimen Container(s)": [
        "BD MAX\u2122M MRSA Sample Buffer Tube"
    ],
    "Instrument(s)/Platform(s)": [
        "BD MAX\u2122 System"
    ],
    "Method(s)/Technology(ies)": [
        "Real-time polymerase chain reaction (PCR)",
        "Fluorogenic target-specific hybridization probe"
    ],
    "Methodologies": [
        "PCR amplification",
        "Automated nucleic acid extraction and detection"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for BD MAX\u2122M MRSA Assay using automated real-time PCR for direct detection of MRSA DNA from nasal swabs",
    "Indications for Use Summary": "Automated qualitative in vitro diagnostic test for direct detection of MRSA DNA from nasal swabs in patients at risk for nasal colonization, aiding in prevention and control of MRSA infections in healthcare settings",
    "fda_folder": "Microbiology"
}